Loading candles…
Nectar Lifesciences Ltd, incorporated in 1995, operates in the pharmaceutical industry with a focus on manufacturing and supplying Cephalosporin Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDF). The company serves global markets, including both regulated and semi-regulated regions. It is recognized as a significant player in the 3rd and 4th generation cephalosporins segment. Its primary business segments include Cephalosporin APIs and Finished Dosage Formulations, providing these products to international customers. There is no available information on founders, key management, subsidiaries, or stock exchange listings.
This page is a live market overview for NECTAR LIFESCIENCES LTD. (NECLIFE) on the NSE. As a listed security, NECTAR LIFESCIENCES LTD. is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for NECLIFE before placing trades on tick2trade.
As of the latest feed, NECLIFE last traded at ₹11.02 on NSE, up ₹0.19 (1.75%) from the previous close of ₹10.83. Today's session range is ₹10.83 – ₹11.2, against a 52-week band of ₹9.3 – ₹22.4. Traded volume today stands at 73.91K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for NECLIFE in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether NECLIFE is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for NECTAR LIFESCIENCES LTD. before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in NECLIFE. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated NECLIFE option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters | 14 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and other business matters | 30 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 23 Jan 2026 |
| Buyback | To consider buyback for equity shares and other business matters | 3 Dec 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 14 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 14 Aug 2025 |
| Other | To consider and approve, inter alia amongst other items, the mode of rewarding of shareholders as contemplated in the explanatory statement to item no. 3 of … | 23 Jul 2025 |
| Audited Results - FY25 | To consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Other business. | 7 Jul 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.